A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Venezuela holds the world's largest proven oil reserves, estimated at 17% of the global total, or 300 billion barrels. In December 2025, the US began a maritime blockade of sanctioned oil or shadow fleet tankers. The 2025–2026 operations are seen by the Trump administration as serving the triple goals of crippling Maduro, disrupting drug trade routes, and getting access to Venezuelan oil; Trump stated that revenue generated would go to the Venezuelan people, US oil companies, and "to the United States of America in the form of reimbursement for the damages caused us by that country". Following the raid, Trump's press conference made clear that oil was a motivation for action in Venezuela. Citing the restructuring of Venezuela's oil industry in 1976 and 2007, Trump, Stephen Miller, and others claimed that Venezuela had stolen oil from US companies. Trump suggested on 5 January that seized oil could be treated as a US asset, asserting the willingness to sell it or add it to the US Strategic Petroleum Reserve. On 9 January, after other sanctioned vessels were seized, and a tanker was returned to Venezuela as part of a joint operation between interim authorities in Venezuela and the US, Trump said: "This tanker is now on its way back to Venezuela, and the oil will be sold through the GREAT Energy Deal, which we have created for such sales." The Trump administration also expressed interest in Venezuela's large deposits of gold and rare earth minerals.
== History and Development == Tagging technology and instrument development occurred at the University of Toronto and DVS Sciences, Inc. CyTOF (cytometry by time of flight) was initially commercialized by DVS Sciences in 2009. In 2014, Fluidigm acquired DVS Sciences to become a reference company in single cell technology. The technology evolved through models like CyTOF, CyTOF2, Helios (CyTOF3) and CyTOF XT, with the latter announced in 2021. In 2022 Fluidigm received a capitol infusion and changed its name to Standard BioTools. In 2023, Standard BioTools introduced the Hyperion XTi Imaging System, advancing Imaging Mass Cytometry (IMC) with capabilities such as whole slide imaging, automated sample processing, and dual imaging/flow cytometry modes. In 2024, the company expanded its high-throughput imaging options with two additional rapid modes and an automated slide loader that can be installed directly on the Hyperion XTi for automatic loading and acquisition of up to 40 slides. Additionally, a 2024 collaboration with Navignostics was announced to develop clinical research applications using the Hyperion XTi system . In 2025, Standard BioTools announced the CyTOF XT Pro System, streamlining workflow with up to 4x faster throughput and software with 21 CFR Part 11 compliance enabling features.
How a policy institute addresses these largely depends on how they work, their ideology vs. evidence credentials, and the context in which they operate including funding opportunities, the degree and type of competition they have and their staff. This functional method addresses the inherit challenge of defining a think tank. As Simon James said in 1998, "Discussion of think tanks...has a tendency to get bogged down in the vexed question of defining what we mean by 'think tank'—an exercise that often degenerates into futile semantics." It is better (as in the Network Functions Approach) to describe what the organisation should do. Then the shape of the organisation should follow to allow this to happen. The following framework (based on Stephen Yeo's description of think tanks' mode of work) is described in Enrique Mendizabal's blog "onthinktanks": First, policy institutes may work in or base their funding on one or more of:
=== Land mine usage === Since 1990, over 11,000 people have been killed or wounded by landmines in Colombia. According to the Presidential Program for Mine Action, between 1982 and the end of 2012, 2,038 people were killed by landmines. Since 2000, casualties from landmines in Colombia have ranged from 1,300 a year to around 550. In the past, the Colombian government laid landmines around 34 military bases to protect key infrastructure, but it renounced their use in 1997. Landmines are primarily used by rebel groups to protect their home bases and illegal drug crops, which fund the conflict. FARC and ELN have deployed antipersonnel mines throughout an estimated area of up to 100 square kilometers. In March 2015, FARC stated that it would begin humanitarian demining in selected parts of Colombia.
Sources: en.wikipedia.org
The vaccines are fully synthesized by chemical synthesis and can be treated as chemical entity. With more advanced solid-phase peptide synthesis (SPPS) using automation and microwave techniques, the production of peptides becomes more efficient. The vaccines do not have any biological contamination since they are chemically synthesized. The vaccines are water-soluble and can be kept stable under simple conditions. The peptides can be specially designed for specificity. A single peptide vaccine can be designed to have multiple epitopes to generate immune responses for several diseases. The vaccines only contain a short peptide chain, so they are less like to lead to allergic or auto-immune responses. Disadvantages:
Poppy seeds from Papaver somniferum are an important food item and the source of poppy seed oil, an edible oil that has many uses. The seeds contain very low levels of opiates and the oil extracted from them contains even less. Both the oil and the seed residue also have commercial uses. The poppy press cake as a residue of the oil pressing can be used as fodder for different animals such as cattle. Especially in the time of the molt of poultry and fancy fowls, the cake is nutritive and fits to their special needs. Next to the animal fodder, poppy offers other by-products. For example, the stem of the plant can be used for energy briquettes and pellets to heat. Poppy seeds are used as a food in many cultures. They may be used whole by bakers to decorate their products or milled and mixed with sugar as a sweet filling. They have a creamy and nut-like flavour, and when used with ground coconut, the seeds provide a unique and flavour-rich curry base. They can be dry roasted and ground to be used in wet curry (curry paste) or dry curry.
=== Mauritius === Mauritius is dependent on oil imports for generating power, and, after a shipment of oil had not arrived as scheduled on 30 March, only 21 days of stock remained in the country. The government arranged for more expensive alternative fuel to be shipped from Singapore, and imposed restrictions to reduce wastage of fuel.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.